Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: Results and implications of the clinical trials Journal Article


Authors: Ramnaraign, B.; Page, D.; Fornier, M.
Article Title: Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: Results and implications of the clinical trials
Abstract: Eribulin mesylate is a novel nontaxane microtubule inhibitor, approved by the US FDA and EMA for the treatment of patients with metastatic breast cancer (MBC). This approval was based upon a pivotal Phase III trial where eribulin demonstrated a survival benefit compared with treatment of physician's choice in MBC patients who received at least two regimens in the metastatic setting. However, a subsequent Phase III study failed to demonstrate superiority of eribulin over capecitabine, in MBC patients who had received two or less regimens in the advanced setting. A pooled analysis of these two studies confirmed the survival benefit of eribulin compared with control. We will review the pivotal early-phase data and Phase III trials of eribulin, describe the role of eribulin for MBC, and summarize future directions in the development of this agent for both metastatic and early-stage breast cancer.
Keywords: capecitabine; staging; radiotherapy; breast neoplasms; trastuzumab; anthracycline; fdg; phase-ii; recurrent; taxane; halichondrin-b analog; e7389
Journal Title: Breast Cancer Management
Volume: 4
Issue: 3
ISSN: 1758-1923
Publisher: Future Medicine  
Date Published: 2015-05-01
Start Page: 135
End Page: 144
Language: English
ACCESSION: WOS:000366182200004
DOI: 10.2217/bmt.15.7
PROVIDER: wos
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Monica Nancy Fornier
    158 Fornier
  2. David B Page
    30 Page